AnaptysBio, Inc. (ANAB): Price and Financial Metrics

AnaptysBio, Inc. (ANAB): $20.88

0.53 (+2.60%)

POWR Rating

Component Grades













Add ANAB to Watchlist
Sign Up

Industry: Biotech



in industry


  • ANAB scores best on the Value dimension, with a Value rank ahead of 69.63% of US stocks.
  • The strongest trend for ANAB is in Quality, which has been heading down over the past 179 days.
  • ANAB ranks lowest in Sentiment; there it ranks in the 1st percentile.

ANAB Stock Summary

  • Of note is the ratio of Anaptysbio Inc's sales and general administrative expense to its total operating expenses; merely 7.11% of US stocks have a lower such ratio.
  • Over the past twelve months, ANAB has reported earnings growth of 189.98%, putting it ahead of 89.18% of US stocks in our set.
  • As for revenue growth, note that ANAB's revenue has grown -15.77% over the past 12 months; that beats the revenue growth of only 8.27% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Anaptysbio Inc, a group of peers worth examining would be ARCT, RNA, CNCE, RAPT, and PTGX.
  • Visit ANAB's SEC page to see the company's official filings. To visit the company's web site, go to

ANAB Valuation Summary

  • ANAB's EV/EBIT ratio is -44.9; this is 253.24% lower than that of the median Healthcare stock.
  • Over the past 56 months, ANAB's EV/EBIT ratio has gone up 25.2.
  • ANAB's price/sales ratio has moved down 11.6 over the prior 56 months.

Below are key valuation metrics over time for ANAB.

Stock Date P/S P/B P/E EV/EBIT
ANAB 2021-08-31 6.9 1.8 -80.6 -44.9
ANAB 2021-08-30 6.8 1.8 -78.7 -42.9
ANAB 2021-08-27 6.9 1.8 -79.8 -44.1
ANAB 2021-08-26 6.7 1.8 -78.0 -42.3
ANAB 2021-08-25 6.8 1.8 -78.7 -43.0
ANAB 2021-08-24 6.8 1.8 -79.0 -43.3

ANAB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANAB has a Quality Grade of C, ranking ahead of 73.88% of graded US stocks.
  • ANAB's asset turnover comes in at 0.294 -- ranking 156th of 682 Pharmaceutical Products stocks.
  • AUPH, OCX, and LFVN are the stocks whose asset turnover ratios are most correlated with ANAB.

The table below shows ANAB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.294 1 0.079
2021-06-30 0.249 1 -0.071
2021-03-31 0.178 1 -0.215
2020-12-31 0.184 1 -0.115
2020-09-30 0.044 1 -0.376
2020-06-30 0.042 1 -0.370

ANAB Price Target

For more insight on analysts targets of ANAB, see our ANAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.33 Average Broker Recommendation 1.79 (Moderate Buy)

ANAB Stock Price Chart Interactive Chart >

Price chart for ANAB

ANAB Price/Volume Stats

Current price $20.88 52-week high $37.89
Prev. close $20.35 52-week low $19.79
Day low $19.80 Volume 167,900
Day high $21.38 Avg. volume 250,538
50-day MA $23.94 Dividend yield N/A
200-day MA $28.54 Market Cap 588.52M

AnaptysBio, Inc. (ANAB) Company Bio

AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.

ANAB Latest News Stream

Event/Time News Detail
Loading, please wait...

ANAB Latest Social Stream

Loading social stream, please wait...

View Full ANAB Social Stream

Latest ANAB News From Around the Web

Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.

AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 Release

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Amgen''s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer |

Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Dynavax Technologies Corporation, Mirati Ther, AnaptysBio Inc. Read Zacks Investment Research''s latest article on | January 21, 2022

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

Yahoo | January 21, 2022

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Yahoo | January 19, 2022

AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don''t make them change their opinion towards a

Insider Monkey | January 12, 2022

Read More 'ANAB' Stories Here

ANAB Price Returns

1-mo -2.84%
3-mo -30.40%
6-mo -32.08%
1-year -17.70%
3-year -70.74%
5-year -22.41%
YTD -39.91%
2021 61.63%
2020 32.31%
2019 -74.53%
2018 -36.67%
2017 N/A

Continue Researching ANAB

Here are a few links from around the web to help you further your research on Anaptysbio Inc's stock as an investment opportunity:

Anaptysbio Inc (ANAB) Stock Price | Nasdaq
Anaptysbio Inc (ANAB) Stock Quote, History and News - Yahoo Finance
Anaptysbio Inc (ANAB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7506 seconds.